Teva's Trouble Was Predicted. Path to Recovery Not as Clear

04:00 EDT 7 Aug 2017 | Topix

Teva Pharmaceutical Industries Ltd. 's proposal to pay $40.5 billion for a generic-drugs division of Allergan Plc. She doubted management's ability to cut the massive debt load they'd be taking on to finance the deal, and even took a swipe at Moody's Investors Service and S&P Global Ratings for having " Last week, Teva proved its critics prescient. The world's biggest maker of generic medicines on Aug. 3 triggered a selloff in its debt and equity by paring a profit forecast and Petach Tikva , Israel-based company slashed its dividend by 75 percent, and said it plans to cut jobs and sell off non-core assets to shed some of its $35 billion debt load.

Original Article: Teva's Trouble Was Predicted. Path to Recovery Not as Clear


More From BioPortfolio on "Teva's Trouble Was Predicted. Path to Recovery Not as Clear"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...